Edition:
United Kingdom

Trisha Roy

Abbott hits all-time high on quarterly revenue beat

22 Jan 2020

Abbott Laboratories Inc's shares rose to an all-time high on Wednesday after the device maker beat Wall Street estimates for quarterly sales on higher demand for its nutrition products and generic drugs.

U.S. FDA panel split over approval of Durect's non-opioid painkiller

16 Jan 2020

Independent experts on an FDA advisory panel on Thursday were split over the approval of Durect Corp's non-opioid painkiller to manage post-surgical pain.

Walgreens misses profit estimates on pharmacy weakness, shares fall 7%

08 Jan 2020

Walgreens Boots Alliance Inc's quarterly profit missed Wall Street estimates on Wednesday, hit by lower payments from insurers on drugs sold at its U.S. pharmacies, knocking back its shares and those of rival CVS Health Corp . | Video

UPDATE 2-Apellis' drug better than Soliris in improving hemoglobin levels in trial

07 Jan 2020

Jan 7 Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than market leader Alexion Pharmaceuticals Inc's Soliris.

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

07 Jan 2020

Jan 7 Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than Alexion Pharmaceuticals Inc's Soliris, in a late-stage study.

FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%

23 Dec 2019

Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia in adults has received approval from the U.S. Food and Drug Administration, sending its shares soaring 85%.

Eisai Inc announces U.S. approval for insomnia drug

23 Dec 2019

Japan-based drugmaker Eisai Co's U.S. subsidiary announced on Sunday that it had received approval from the U.S. Food and Drug Administration for its insomnia treatment in adult patients.

UPDATE 2-Biohaven Pharma to continue late-stage study of Alzheimer's treatment

06 Dec 2019

Dec 6 Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%.

World News